Skip to main navigation Skip to search Skip to main content

Abstract

Overexpression of HE R-2 and VEGF plays a key role in the development and metastasis of several human cancers. Many FDA-approved therapies targeting both HE R-2 (Trastuzumab, Herceptin) and VEGF (Bevacizumab, Avastin) are expensive, have unacceptable toxicities and are often associated with the development of resistance. Here, we evaluate the dual antitumor effects of combining designed particular HE R-2 peptide vaccine with VEGF peptide mimics. In vitro, HE R-2 phosphorylation and antibody-dependent cellular toxicity were used to validate whether combining HE R-2- and VEGFtargeting therapies would be effective. Moreover, a two-pronged approach was tested in vivo: (1) active immunotherapy with conformational HE R-2 B-cell epitope vaccines and (2) anti-angiogenic therapy with a peptide structured to mimic VEGF. A transplantable BALB/c mouse model challenged with TUBO cells was used to test the effects of the HE R-2 peptide vaccine combined with VEGF peptide mimics. Tumor sections after treatment were stained for blood vessel density and actively dividing cells. Our results show that immunization with an HE R-2 peptide epitope elicits high affinity HE R-2 native antibodies that are effective in inhibiting tumor growth in vivo, an effect that is enhanced by VEGF peptide mimics. We demonstrate that the combination of HE R-2 and VEGF peptides induces potent anti-tumor and anti-angiogenic responses.

Original languageEnglish
Pages (from-to)1048-1060
Number of pages13
JournalOncoImmunology
Volume1
Issue number7
DOIs
StatePublished - 2012

Keywords

  • Angiogenesis
  • Antibodies
  • Peptides
  • Peptides/epitopes
  • Peptidomimetic

Fingerprint

Dive into the research topics of 'Combined vaccination with her-2 peptide followed by therapy with vegf peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo'. Together they form a unique fingerprint.

Cite this